Download PDF
Zeitschrift für Palliativmedizin 2008; 9(3): 99-119
DOI: 10.1055/s-2008-1067538
CME-Fortbildung

© Georg Thieme Verlag KG Stuttgart · New York

Palliativmedizin bei neurologischen Erkrankungen

Palliative Care in Neurological DisordersH.  Golla, R.  Voltz, S.  Lorenzl, G.  D.  Borasio
Further Information

Publication History

Publication Date:
10 September 2008 (online)

Also available at
    Permissions and Reprints

Abstract

From the start of modern hospice and palliative care, patients with non-tumor conditions were also cared for. Among those, neurological disorders constitute the largest group of patients. In Germany, only recently, specialized palliative home care has become mandatory part of the national ehealth care system. The now published frameworks for that only speak of needs and not disorders, therefore paving the way for more neurological patients within palliative care structures in the future. This article provides an up-to-date overview on palliative care for patients with brain tumors, amyotrophic lateral sclerosis, Parkinson syndromes and multiple sclerosis.

Literatur

  • 1 Mintz A, Perry J, Spithoff K. et al . Management of single brain metastasis: a practice guideline.  Curr Oncol. 2007;  14 131-143
    CrossrefPubMedGoogle Scholar
  • 2 Prados M D, Levin V. Biology and Treatment of Malignant Glioma.  Seminars in Oncology. 2000;  27 (Suppl. 6) 1-10
    PubMedGoogle Scholar
  • 3 Chen G, Huynh M, Chen A. et al . Chemotherapy for brain metastases in small-cell lung cancer.  Clin Lung Cancer. 2008;  9 35-38
    CrossrefPubMedGoogle Scholar
  • 4 Behar R, Abu Rkih R. Does the patient with a primary brain tumour need hospice? Abstracts of the 7th. Congress of EAPC.  Eur J Pall Care. 2001;  12 120
    PubMedGoogle Scholar
  • 5 Bausewein C, Borasio G D, Voltz R. Primary Brain Tumours. In: Doyle D, Hanks G, Cherny N, Calman K, eds Oxford Textbook of Palliative Medicine. 3rd. ed. Oxford; Oxford University Press 2004: 727-730
    Google Scholar
  • 6 Davies E, Higginson I J. Communication, information and support for adults with malignant cerebral glioma: a systematic literature review.  Support Care Cancer. 2003;  11 21-29
    PubMedGoogle Scholar
  • 7 Burchardi N, Rauprich O, Hecht M. et al . Discussing living wills. A qualitative study of a German sample of neurologists and ALS patients.  J Neurol Sci. 2005;  237 67-74
    CrossrefPubMedGoogle Scholar
  • 8 Adelbratt S, Strang P. Death anxiety in brain tumour patients and their spouses.  Palliative Medicine. 2000;  14 499-507
    CrossrefPubMedGoogle Scholar
  • 9 Forsyth P A, Posner J B. Headaches in patients with brain tumors: a study of 111 patients.  Neurology. 1993;  43 1678-1683
    PubMedGoogle Scholar
  • 10 Vecht C J, Hovestadt A, Verbiest H B. et al . Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumours: a randomized study of doses of 4, 8 and 16 mg per day.  Neurology. 1994;  44 675-680
    PubMedGoogle Scholar
  • 11 Brogna C, Gil Robles S, Duffau H. Brain tumors and epilepsy.  Expert Rev Neurother. 2008;  8 941-955
    CrossrefPubMedGoogle Scholar
  • 12 Kurthen M, Bauer J, Janzen C. et al .Status epilepticus im Erwachsenenalter. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 20-27
    Google Scholar
  • 13 van Breemen M S, Wilms E B, Vecht C J. Epilepsy in patients with brain tumors: epidemiology, mechanisms, and management.  Lancet Neurol. 2007;  6 421-430
    CrossrefPubMedGoogle Scholar
  • 14 Elger C E, Bauer J, Janzen C. et al .Epilepsie im Erwachsenenalter. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 8-17
    Google Scholar
  • 15 Lorenzl S, Mayer S, Noachtar S. et al . Nonconvulsive status epilepticus in terminally ill patients – a diagnostic and therapeutic challenge.  J Pain Symptom Manage. 2008;  36 200-205
    CrossrefPubMedGoogle Scholar
  • 16 Bausewein C, Roller S, Voltz R. Delirantes Syndrom. Leitfaden Palliativmedizin Palliative Care. 3. Aufl. München; Urban & Fischer Elesevier 2007: 326-331
    Google Scholar
  • 17 Bausewein C, Hau P, Voltz R. et al . How do patients with brain tumours die?.  Palliat Med. 2003;  17 558-559
    CrossrefPubMedGoogle Scholar
  • 18 Oliver D, Borasio G D, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis – From Diagnosis to Bereavement. 2nd. ed. Oxford; Oxford University Press 2006
    Google Scholar
  • 19 Borasio G D, Sloan R, Pongratz D E. Breaking the news in amyotrophic lateral sclerosis.  J Neurol Sci. 1998;  160 (Suppl. 1) S127-S133
    CrossrefPubMedGoogle Scholar
  • 20 Borasio G D, Husemeyer I M. Ernährung bei Schluckstörungen. 6. Aufl. Stuttgart; Kohlhammer 2004
    Google Scholar
  • 21 Neudert C, Oliver D, Wasner M. et al . The course of the terminal phase in patients with amyotrophic lateral sclerosis.  J Neurol. 2001;  248 612-616
    CrossrefPubMedGoogle Scholar
  • 22 Miller R G, Rosenberg J A, Gelinas D F. et al . Practice Parameter: The care of the patient with amyotrophic lateral sclerosis.  Neurology. 1999;  52 1311-1323
    PubMedGoogle Scholar
  • 23 Borasio G D, Voltz R. Discontinuation of life support in patients with amyotrophic lateral sclerosis.  J Neurol. 1998;  245 717-722
    CrossrefPubMedGoogle Scholar
  • 24 Mazzocato C, Buclin T, Rapin C H. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial.  Ann Oncol. 1999;  10 1511-1514
    CrossrefPubMedGoogle Scholar
  • 25 Ganzini L, Johnston W S, McFarland B H. et al . Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide.  N Engl J Med. 1998;  339 967-973
    CrossrefPubMedGoogle Scholar
  • 26 Giess R, Naumann M, Werner E. et al . Injections of botulinum toxin A into the salivary glands improve sialorrhea in amyotrophic lateral sclerosis.  J Neurol Neurosurg Psychiatry. 2000;  69 121-123
    Google Scholar
  • 27 Sykes N, Thorns A. The use of opioids and sedatives at the end of life.  Lancet Oncology. 2003;  4 312-318
    CrossrefPubMedGoogle Scholar
  • 28 Mark M H. Lumping and splitting the Parkinson plus syndromes: Dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortico-basal ganglionic degeneration.  Neurol Clin. 2001;  19 607-627
    CrossrefPubMedGoogle Scholar
  • 29 Bunting-Perry L K. Palliative care in Parkinson's disease: implications for neuroscience nursing.  J Neurosci Nurs. 2006;  38 106-113
    CrossrefPubMedGoogle Scholar
  • 30 Daniele A, Moro E, Bentivoglio A R. Zolpidem in progressive supranuclear palsy.  N Engl J Med. 1999;  341 543-544
    CrossrefPubMedGoogle Scholar
  • 31 Nath U, Ben-Shlomo Y, Thomson R G. et al . Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study.  Neurology. 2003;  60 910-916
    CrossrefPubMedGoogle Scholar
  • 32 Papapetropoulos S, Singer C, McCorquodale D. et al . Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP).  Parkinsonism Relat Disord. 2005;  11 459-463
    CrossrefPubMedGoogle Scholar
  • 33 Flachenecker P. Epidemiology of neuroimmunological diseases.  J Neurol. 2008;  255 308
    PubMedGoogle Scholar
  • 34 Matthews B. Symptoms and signs of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, Mc Donald I, Matthews B, Wekerle H, eds McAlpine's Multiple Sclerosis. 3rd. ed. Oxford; Elsevier 1998: 145-191
    Google Scholar
  • 35 Multiple Sclerosis Therapy Consensus Group (MSTCG) .Basic and escalating immunomodulatory treatments in multiple sclerosis – Current therapeutic recommendations. J Neurol 2008 [im Druck]
    Google Scholar
  • 36 Higginson I J, Hart S, Silber E. et al . Symptom prevalence and severity in people severely affected by multiple sclerosis.  J Palliat Care. 2006;  22 158-165
    PubMedGoogle Scholar
  • 37 Edmonds P, Vivat B, Burman R. et al . Loss and change: experiences of people severely affected by multiple scerosis.  Palliative Medicine. 2007;  21 101-107
    CrossrefPubMedGoogle Scholar
  • 38 Edmonds P, Vivat B, Burman R. et al . „Fighting for everything”: service experiences of people severely affected by multiple sclerosis.  Multiple Sclerosis. 2007;  13 660-667
    CrossrefPubMedGoogle Scholar
  • 39 Kümpfel T, Hoffmann L A, Pöllmann W. et al . Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists.  Palliate Med. 2007;  21 109-114
    PubMedGoogle Scholar
  • 40 Stenager E N, Stenager E, Koch-Henrikson N. et al . Suicide and multiple sclerosis: an epidemiological investigation.  J Neurol Neurosurg Psychiatry. 1992;  55 542-545
    CrossrefPubMedGoogle Scholar
  • 41 Feinstein A. An examination of suicidal intent in patients with multiple sclerosis.  Neurology. 2002;  59 674-678
    PubMedGoogle Scholar
  • 42 van der Wal G, Onwuteaka-Philipsen B D. Cases of euthanasia and assisted suicide reported to the public prosecutor in North Holland over 10 years.  BMJ. 1996;  312 612-613
    PubMedGoogle Scholar
  • 43 Henze T, Rieckmann P, Toyka K V. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society . Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.  Eur Neurol. 2006;  56 78-105
    CrossrefPubMedGoogle Scholar
  • 44 Rieckmann P, Toyka K, Fasshauer E. Diagnostik und Therapie der Multiplen Sklerose. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 298-316
    Google Scholar
  • 45 Noth J, Dietz V, Ochs G. Spastik. In: Diener HC, Putzki N, Berlit P et al., Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2005: 596-603
    Google Scholar
  • 46 Bever Jr C T, Young D, Anderson P A. et al . The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.  Neurology. 1994;  44 (6) 1054-1059
    CrossrefPubMedGoogle Scholar
  • 47 Panitch H S, Thisted R A, Smith R A. et al . Randomized, controlled trial of dextromethorphan / quinidine for pseudobulbar affect in multiple sclerosis.  Ann Neurol. 2006;  59 780-787
    CrossrefPubMedGoogle Scholar

Prof. Dr. Raymond Voltz

Klinik für Palliativmedizin, Uniklinik Köln

Kerpener Straße 62

50924 Köln

Email: raymond.voltz@uk-koeln.de